Krystal Biotech Cash from Financing (Quarterly) Analysis

Krystal Biotech Inc (KRYS)

159.99 -1.61 (-1.00%) USD | NASDAQ | May 31, 16:00

160.02 +0.02 (+0.02%) After-Hours: 20:00

Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Upgrade now.

Date	Value
March 31, 2024	10.58M
December 31, 2023	2.619M
September 30, 2023	13.39M
June 30, 2023	185.27M
March 31, 2023	1.474M
December 31, 2022	3.069M
September 30, 2022	2.12M
June 30, 2022	30.70M
March 31, 2022	-0.542M
December 31, 2021	202.07M
September 30, 2021	1.508M
June 30, 2021	-0.199M
March 31, 2021	144.30M
December 31, 2020	0.141M
September 30, 2020	0.166M

Date	Value
June 30, 2020	117.47M
March 31, 2020	0.243M
December 31, 2019	0.299M
September 30, 2019	13.17M
June 30, 2019	94.02M
March 31, 2019	0.04M
December 31, 2018	64.29M
September 30, 2018	9.549M
June 30, 2018	0.004M
March 31, 2018	0.006M
December 31, 2017	-0.693M
September 30, 2017	50.16M
June 30, 2017	1.999M
March 31, 2017	0.30M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

-0.542M

Minimum

Mar 2022

202.07M

Maximum

Dec 2021

41.09M

Average

2.844M

Median

Cash from Financing (Quarterly) Benchmarks

Axsome Therapeutics Inc	-1.187M
Madrigal Pharmaceuticals Inc	573.71M
Alnylam Pharmaceuticals Inc	28.91M
Catalyst Pharmaceuticals Inc	141.05M
Cytokinetics Inc	103.79M

Cash from Financing (Quarterly) Related Metrics

Cash from Operations (Quarterly)	15.89M
Cash from Investing (Quarterly)	-25.98M
Free Cash Flow	-54.44M
Free Cash Flow Per Share (Quarterly)	0.4994
Free Cash Flow to Equity (Quarterly)	14.63M
Free Cash Flow Yield	-1.20%